SPRO Stock Skyrockets on Breakthrough Oral Antibiotic Data

stockanalysis.com stockanalysis.com Spero’s shares have roughly doubled this year, hitting around $2.29 on Oct 20, 2025. The stock has traded in a broad range stockanalysis.com. Trading volume is light, and the stock’s beta indicates volatility. In recent days, SPRO has climbed on the back of the Phase 3 data. The 50-day moving average and 200-day average suggest the trend has turned positive after the spring rally. Year-to-date, SPRO is up ~120%, well above the small-cap biotech average.